NCT05098197

A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)

Recruiting now EARLY_PHASE1 Last updated 11 December 2025

What this trial tests

EARLY_PHASE1 trial testing Tumor Infiltrating Lymphocyte in Advanced Liver Cancers in 50 participants. Currently enrolling.

Timeline

26 September 2021

Primary endpoint
25 September 2026

25 September 2026

Quick facts

Lead sponsor	Shanghai Juncell Therapeutics
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	26 September 2021
Primary completion	25 September 2026
Estimated completion	25 September 2026
Sites	1 location across China

Drugs / interventions tested

• Tumor Infiltrating Lymphocyte — full drug profile →

Conditions studied

• Advanced Liver Cancers — all drugs for Advanced Liver Cancers →
• Tumor Infiltrating Lymphocyte — all drugs for Tumor Infiltrating Lymphocyte →
• Treatment Side Effects — all drugs for Treatment Side Effects →
• Effects of Immunotherapy — all drugs for Effects of Immunotherapy →

Sponsor

Shanghai Juncell Therapeutics — full company profile →

Who can join

Adults 18 to 75, any sex, with Advanced Liver Cancers or Tumor Infiltrating Lymphocyte. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced hepatobiliary-pancreatic cancers. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. The next wave of cellular immunotherapies in pancreatic cancer.
   Yeo D, Giardina C, Saxena P, Rasko JEJ. · · 2022 · cited 63× · PMID 35229033 · DOI 10.1016/j.omto.2022.01.010
2. Consensus, debate, and prospective on pancreatic cancer treatments.
   Wang J, Yang J, Narang A, He J, et al · · 2024 · cited 56× · PMID 39390609 · DOI 10.1186/s13045-024-01613-x
3. Recent clinical researches and technological development in TIL therapy.
   Matsueda S, Chen L, Li H, Yao H, et al · · 2024 · cited 23× · PMID 39264449 · DOI 10.1007/s00262-024-03793-4
4. Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances.
   Wang X, Yuan Z, Li Z, He X, et al · · 2024 · cited 12× · PMID 38426090 · DOI 10.3389/fimmu.2024.1354313
5. Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought.
   Agostini A, Orlacchio A, Carbone C, Guerriero I. · · 2022 · cited 12× · PMID 35711414 · DOI 10.3389/fimmu.2022.876291
6. Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies.
   Sherpally D, Manne A. · · 2025 · cited 3× · PMID 40002184 · DOI 10.3390/cancers17040589
7. Immune-Based Strategies for Pancreatic Cancer in the Adjuvant Setting.
   Liang KL, Azad NS. · · 2025 · cited 2× · PMID 40227779 · DOI 10.3390/cancers17071246
8. Tumor-Infiltrating Natural Killer Cell Characterization in Pancreatic Ductal Adenocarcinoma.
   Maia A, Calá H, de Sousa E, Lérias JR, et al · · 2026 · PMID 42121898 · DOI 10.3390/cells15090797